Twenty seven patients with cystic fibrosis under the age of 12 years and 27 matched patients with asthma were followed up in a prospective study for one year. The isolation rate of non-capsulated strains ofHaemophilus influenzae from cough swabs and sputum specimens taken at routine clinic visits every two months was significantly greater in cystic fibrosis than in asthma. Haemophilus parainfluenzae was equally common in both groups. During exacerbations the isolation rate of H influenzae in cystic fibrosis was significantly greater than at other times, whereas in asthma there was no significant difference.
In recent years, non-capsulated Haemophilus influenzae has become well established as an important human pathogen in both adults and children.1-3 Non-capsulated strains of H influenzae and Haemophilus parainfluenzae colonise the lower respiratory tracts of patients with cystic fibrosis but may also be found in the upper respiratory tracts of normal children. 4 Some cystic fibrosis centres adopt a policy of treating all patients from whom Haemophilus spp have been isolated, irrespective of the clinical state of the patient.5 H influenzae and H parainfluenzae have been subdivided by Kilian on the basis of three biochemical characteristics (ornithine decarboxylation, indole production, and urea hydrolysis) into several biotypes. 6 Biotype I of H influenzae, which is known to be associated with acute otitis media in normal children,3 was isolated significantly more often from patients with cystic fibrosis than from healthy controls.7 To assess the importance of H influenzae and H parainfluenzae in cystic fibrosis and the value of biotyping, we conducted a prospective study to determine the rates of isolation and the distribution of biotypes from the respiratory tracts of children with cystic fibrosis. Children with asthma were used as controls because they were likely to have increased respiratory secretions without significant bacterial infection.
Patients and methods

PATIENTS
All patients with cystic fibrosis under the age of 12 years who lived within easy reach of the hospital were invited to take part in the study. The next suitable patient seen in the asthma clinic, matched for age and sex, was invited to act as a control. Consent was obtained from the parents and the study was approved by the hospital ethical committee. Patients were seen routinely every two months and weekly during acute respiratory exacerbations. At each visit weight and height were recorded and where possible lung function tests were performed using a Wright peak flow meter and an electronic spirometer. The best of three readings was recorded in each case and was expressed as a percentage of the predicted value for height. Pulse, respiratory rate, and physical signs were scored by one of us (RJR) and the parents were asked to score symptoms of cough, wheeze, and breathlessness on a scale of 0 (none) to 4 (severe). The two scores were added together for analysis. At the start of the study, peak flow records and symptom charts were kept for two weeks to assess baseline variability during a period when the child was well. The parents contacted the hospital at any time when the child was unwell with increased cough, wheezing, or breathlessness and peak flow records and symptom scores were recorded until symptoms had resolved.
During acute exacerbations, patients with cystic fibrosis received a two week course of amoxycillin. Those aged less than 1 , and the median Chrispin-Norman x ray score'2 was 6 (range [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Five patients with cystic fibrosis were chronically infected with P aeruginosa. In the asthma group, 19 patients were taking inhaled steroids and six were taking inhaled sodium cromoglycate. Twenty one patients in each group were able to perform reliable respiratory function tests.
There were 80 exacerbations in the group with cystic fibrosis and 34 in the group with asthma. Exacerbations were associated with a fall in mean peak expiratory flow rate (PEFR) and forced expiratory volume in one second (FEVI) in both groups (p<0 05) and a rise in mean clinical score. There was an improvement in mean PEFR and FEV, by the second week of antibiotic treatment (p<005) in the group with cystic fibrosis (figure).
Four hundred and ninety cough swabs or sputum specimens (cystic fibrosis, n=303 and asthma, n= 187) were examined between January and December 1988. H influenzae was isolated on at least one occasion from 21 patients with cystic fibrosis and eight with asthma (p<0-001), and on three or more occasions from six cystic fibrosis patients but no asthmatics. All strains of H influenzae isolated were non-capsulated. H parainfluenzae was isolated on at least one occasion from six patients with cystic fibrosis and two with asthma. and all except one produced ,B lactamase. Five of eight ,1 lactamase producing strains were biotype V. Two strains ofH parainfluenzae were ampicillin resistant.
In patients with cystic fibrosis from whom H influenzae only was isolated during an exacerbation, a 14 day course of oral amoxycillin was always associated with a clinical response.
Eradication of H influenzae was achieved on 15 out of 22 (70%) occasions. It is our practice to treat all patients with cystic fibrosis from whom S aureus is isolated, irrespective of symptoms.
Discussion
The role of non-capsulated H influenzae in adults with lower respiratory tract infections is now widely recognised, but in children its role remains unresolved. This is because it is frequently isolated from the upper respiratory tract in normal children and it is known that invasive infections in children are almost always due to capsulated type b strains of H influenzae. Nevertheless, non-capsulated strains are undisputed pathogens of otitis media and sinusitis in children,3 and in a large study of community acquired pneumonia in children, more than half the strains ofH influenzae producing pneumonia were non-capsulated. '3 The results of this study suggest that H influenzae is a significant pathogen in children with cystic fibrosis. H influenzae was more frequently isolated from the lower respiratory tract in cystic fibrosis than in asthma. Further and may be effective in children.
The isolation rate of viruses in this study was low, but nasopharyngeal cultures taken on the first day of illness and paired blood samples for viral serology might have yielded more positive results. 17 Secondary bacterial infection may occur in cystic fibrosis as a result of damage to the respiratory epithelium during viral infection.
H influenzae may colonise the upper respiratory tract initially and then migrate to cause lower respiratory tract infections in the damaged bronchi of cystic fibrosis patients. H influenzae is capable of producing histamine in vitro, '8 which might contribute to inflammation and airflow obstruction in cystic fibrosis. This study has shown that antibiotic treatment for H influenzae was associated with clinical improvement and with the eradication of the organism in most cases. Therefore, we feel that antimicrobial treatment should be considered seriously in patients with cystic fibrosis from whom noncapsulated H influenzae is isolated, particularly during exacerbations.
